Healthcare Diagnostics Powered by neuropacs™
Elevating Diagnostic Accuracy and Patient Care
For radiologists and neurologists, distinguishing between complex neurodegenerative disorders is one of the most pressing clinical challenges. neuropacs™ provides AI-driven, imaging-enabled diagnostic support that enhances accuracy, reduces uncertainty, and empowers physicians to deliver better care.
The Challenge in Neurodiagnostics
Overlapping symptoms
Overlapping symptoms between Parkinson’s, MSAp, PSP, and other conditions often lead to misdiagnosis.
Lack of sensitivity
Standard volumetric MRI lacks the sensitivity to detect subtle microstructural alterations associated with early disease progression.
Ineffective interpretation
Variability in interpretation can reduce confidence and delay treatment decisions.
Benefits for Radiologists & Neurologists
Reduce misdiagnosis and increase confidence in complex cases. Faster, more precise diagnoses support timely treatment and improved standard of care.
- Higher Diagnostic Accuracy
- Earlier Detection
- Standardized Reporting
- Better Patient Outcomes
Objective Imaging Biomarkers
Provides quantitative measures of disease presence, severity, and progression.
AI-Powered Diagnostic Insights
Achieves up to 96% precision in distinguishing Parkinsonian variants.
Clinical Decision Support
Offers stratified diagnostic outputs that aid radiologists and neurologists in making confident, evidence-based decisions.
Seamless Workflow Integration
Delivered via secure cloud-based workflow
Unmatched Accuracy
Up to 98% precision in distinguishing PD from MSAp and PSP
Whether supporting clinical decision-making or powering trial success, neuropacs™ provides exclusive methodologies, actionable insights, and a seamless integration into existing imaging workflows.
96%
Up to 96% accuracy
21 sites
involved in most recent clinical trial
15+
Years of data collected
1000s
Unique datasets analyzed
Validated, Trusted, Ready
neuropacs™ leverages proprietary, patent-protected techniques that combine:
-
AI-driven diagnostics trained on
harmonized multi-site data - Exclusive Patent: US 10,758,170 for Parkinsonism
- Patent pending for Dementia and Alzheimer’s
- Free-Water Imaging (FWI): A powerful diffusion MRI method that enhances early disease detection
- FDA DeNovo device clearance: anticipated in 2025
Our Patents
Patents and patent-pending filings cover multiple neurodegenerative indications, including:
•Alzheimer’s Disease
•Parkinson’s Disease
•Multiple System Atrophy (MSA)
•Progressive Supranuclear Palsy (PSP)
•Dementia with Lewy Bodies
•Amyotrophic Lateral Sclerosis (ALS)
•Motor Neuron Disease (MND)
•Corticobasal Degeneration
•Huntington’s Disease Multiple Sclerosis (MS)
Evidence and Expertise
neuropacs™ is the result of decades of research led by world-class clinicians and neuroscientists from:
•University of Florida
•UF Health Norman Fixel Institute for Neurological Diseases
Validated across thousands of MRI scans and multiple clinical trials, neuropacs™ delivers:
•Peer-reviewed results
•Academic rigor
•Real-world applicability
•FDA enabled
•Most sensitive platform available
Partner with neuropacs™
neuropacs™ is more than a diagnostic tool — it’s a clinical ally for physicians dedicated to improving outcomes in neurodegenerative care.